Align Technology's Invisalign Palatal Expander System Gains Regulatory Approval in India, Now Available for Broad Patient Use

Reuters
15 Jul
Align Technology's Invisalign Palatal Expander System Gains Regulatory Approval in India, Now Available for Broad Patient Use

Align Technology Inc., a global leader in medical device manufacturing, has announced that its Invisalign Palatal Expander System has received Class B medical device approval from the Central Drugs Standard Control Organization (CDSCO) in India. This approval allows the device to be commercially available in the country, expanding treatment options for growing children, teens, and adults. The Invisalign Palatal Expander System offers a modern, easily removable alternative to traditional expanders, using direct 3D printed technology for effective skeletal and dental expansion. This development underscores Align's commitment to advancing digital orthodontics across the Asia Pacific region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Align Technology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250714711796) on July 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10